Abstract: The soluble urokinase-type plasminogen activator receptor (suPAR) is a new type of biomarkers, and can be used for a variety of diagnosis, evaluation and prognosis of many diseases. Numerous studies have proved that suPAR is closely related to inflammatory diseases, cardiovascular diseases, autoimmune diseases, tumors and chronic liver diseases. In recent years, important insights have been gained into the pathogenic role of suPAR in glomerular diseases, including focal segmental glomerular sclerosis, membranous nephropathy, minimal change disease, lgA nephropathy, diabetic nephropathy, and lupus nephritis etc. Here, we review the role of suPAR in glomerular diseases.